权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Washington University SPORE in Pancreatic Cancer

华盛顿大学 SPORE 在胰腺癌中的应用

基本信息

批准号：
9146190
负责人：
WILLIAM G HAWKINS
金额：
$ 218.67万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-28 至 2021-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9146190
关键词：
Antineoplastic Agents Basic Science Biometry Cancer Biology Cancer Center Cancer Research Project Cancer Vaccines Clinic Clinical Clinical Sciences Clinical Trials Collaborations Dendritic Cells Development Diagnosis Disabled Persons Disease Drug Targeting Ensure Environment Female Fostering Genomics Goals Image Imaging Techniques Immune response Immunologics Immunology Immunosuppression Immunotherapy Individual Institution KRAS2 gene Ligands Malignant neoplasm of pancreas Mentors Minority Mission Monitor Morbidity - disease rate Myelogenous Nebraska North Carolina Pancreatic Ductal Adenocarcinoma Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Process Radiology Specialty Recruitment Activity Research Research Infrastructure Research Personnel Research Project Grants Resource Sharing Resources Science Specialized Program of Research Excellence Suppressor-Effector T-Lymphocytes Testing Therapeutic Therapeutic Clinical Trial Therapeutic Trials Tissues Training Translational Research Translations Universities Washington Work animal imaging cancer therapy career clinical practice design drug development improved inhibitor/antagonist innovation inter-institutional leukemia malignant breast neoplasm migration mortality mutant novel novel diagnostics novel strategies novel therapeutic intervention novel therapeutics patient population preclinical study prevent programs response small molecule inhibitor small molecule therapeutics tumor tumor microenvironment

项目摘要

PROJECT SUMMARY The Washington University Pancreatic Cancer Specialized Program of Research Excellence (SPORE) is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical sciences, and our teams leverage individual expertise in immunology, drug development, genomics, and imaging to develop novel diagnostic and therapeutic approaches to PDAC. This SPORE includes four research projects, an administrative core, two shared-resources cores, and developmental research and career enhancement programs. With the help of our External and Internal Advisory Boards, we have intentionally selected the projects that have the greatest potential to impact PDAC. All four of our selected projects include a therapeutic trial, and two take advantage of immunologic discoveries made at WU. We have two projects that utilize small molecule inhibitors of pathways that are known to be active in PDAC. The four projects in our application are designed to have significant potential to change clinical practice within five years. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW V-49 Project 3: Combination Inhibition of ERK for Pancreatic Cancer Treatment Project 4: Translation and Preclinical Studies of a Personalized Pancreatic Cancer Vaccine Our long-term goal is to improve survival of patients diagnosed with PDAC. To achieve this, we will promote institutional and inter-institutional collaborative science, with an emphasis on translation. We expect that no singular approach will solve PDAC, and fully commit to supporting the development of novel ideas and young investigators. Our SPORE will provide access to pancreatic cancer-specific resources to facilitate this mission.

项目总结